Literature DB >> 24900733

Inhibitors of Bruton's Tyrosine Kinase (Btk) May Treat Inflammation, Immunological Disorders, and Cancer.

Ahmed F Abdel-Magid1.   

Abstract

Entities:  

Year:  2013        PMID： 24900733      PMCID： PMC4027502          DOI： 10.1021/ml400220w

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


× No keyword cloud information.
  3 in total

Review 1.  Targeting the B cell receptor pathway in chronic lymphocytic leukemia.

Authors:  Matthew S Davids; Jennifer R Brown
Journal:  Leuk Lymphoma       Date:  2012-12

Review 2.  Bruton's tyrosine kinase as a molecular target in treatment of leukemias and lymphomas as well as inflammatory disorders and autoimmunity.

Authors:  Fatih M Uckun; Sanjive Qazi
Journal:  Expert Opin Ther Pat       Date:  2010-09-10       Impact factor: 6.674

Review 3.  Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain.

Authors:  Abdalla J Mohamed; Liang Yu; Carl-Magnus Bäckesjö; Leonardo Vargas; Rani Faryal; Alar Aints; Birger Christensson; Anna Berglöf; Mauno Vihinen; Beston F Nore; C I Edvard Smith
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988
  3 in total
  1 in total

1.  Inhibition of Bruton's Tyrosine Kinase Protects Against Burn Sepsis-Induced Intestinal Injury.

Authors:  Jia Wan; Xi Yu; Jia-Qi Niu; Le Qiu; Fei Wang; Xu-Lin Chen
Journal:  Front Med (Lausanne)       Date:  2022-02-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.